Qiagen N.V. (QGEN)
Upgrades & Downgrades
Latest QGEN news
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
1 February 2023
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
17 January 2023
VENLO, Netherlands--( BUSINESS WIRE )--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.
QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails
12 January 2023
The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
12 January 2023
Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
10 January 2023
QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
14 December 2022
QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
25 November 2022
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
23 November 2022
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
10 November 2022
The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).